drugset / Trial / NCT05468177
Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer
Phase 2
Unknown
66 enrolled
Tongji Hospital
Central Hospital of Xiaogan · collabEzhou Central Hospital · collabHuangshi Central Hospital · collabJingzhou Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
We plan to evaluate the efficacy and safety of cetuximab combined with anti-PD-1 and mFOLFOX6 in the treatment of RAS/BRAF WT locally advanced or metastatic right colon cancer
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |
| Background | LV | Unknown | 400 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |